It’s only fair to share… Daridorexant Molecular FormulaC23H23ClN6O2 Average mass450.921 Da [(2S)-2-(5-Chloro-4-methyl-1H-benzimidazol-2-yl)-2-methyl-1-pyrrolidinyl][5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone 1505484-82-1 [RN] Methanone, [(2S)-2-(5-chloro-4-methyl-1H-benzimidazol-2-yl)-2-methyl-1-pyrrolidinyl][5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl]- ACT-541468, , Nemorexant FDA APPROVED 2022, 1/7/2022, To treat insomnia, Quviviq Daridorexant HCl CAS#: 1792993-84-0 (HCl) Chemical Formula: C23H24Cl2N6O2 Molecular Weight: 487.39 Elemental Analysis: C, 56.68; H, 4.96; Cl, 14.55; N, 17.24; O, 6.57 Methanone, ((2S)-2-(6-chloro-7-methyl-1H-benzimidazol-2-yl)-2-methyl-1-pyrrolidinyl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)-, hydrochloride (1:1) Daridorexant HCl; Daridorexant hydrochloride; …
Tag «Insomnia»
Nemorexant
It’s only fair to share… Nemorexant ACT-541468, UNII LMQ24G57E9 [(2S)-2-(5-Chloro-4-methyl-1H-benzimidazol-2-yl)-2-methyl-1-pyrrolidinyl][5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone 1505484-82-1 [RN] LMQ24G57E9 Methanone, [(2S)-2-(5-chloro-4-methyl-1H-benzimidazol-2-yl)-2-methyl-1-pyrrolidinyl][5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl]- Originator Actelion Pharmaceuticals Developer Idorsia Pharmaceuticals Class Sleep disorder therapies Mechanism of Action Orexin receptor type 1 antagonists; Orexin receptor type 2 antagonists Phase III Insomnia 19 Oct 2018 Idorsia Pharmaceuticals plans a phase I trial for Liver disorders (Hepatic impairment) in November 2018 (PO) (NCT03713242) 09 Oct …